A β-catenin nuclear inhibitor such as PRI-724 or tegavivint would theoretically not work on the osteosarcoma tumors that express WNT5A or WNT5B (~50% of tumors) or those that do not express a WNT ligand (~30% of tumors), and conversely, a ROR1 inhibitor would not work on osteosarcoma tumors that express WNT10B only. Here, WNT5A is linked to osteosarcoma.